Back to top
more

Editas Medicine (EDIT)

(Delayed Data from NSDQ)

$3.51 USD

3.51
1,941,434

-0.08 (-2.23%)

Updated Sep 9, 2024 04:00 PM ET

After-Market: $3.52 +0.01 (0.28%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug

by Zacks Equity Research

Editas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe.

A Comprehensive Guide to Genomic ETFs

by Zacks Equity Research

Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.

BeiGene, Ltd. (BGNE) Soars 15.5%: Is Further Upside Left in the Stock?

by Zacks Equity Research

BeiGene, Ltd. (BGNE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Editas (EDIT) Down 20.7% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Editas' (EDIT) EDIT-301 Gets Orphan Drug Tag for Beta Thalassemia

by Zacks Equity Research

The FDA bestows an Orphan Drug designation to Editas' (EDIT) investigational gene therapy, EDIT-301, for treating beta thalassemia. Shares up in after-hours trading.

Editas' (EDIT) Q1 Loss Narrows, Revenues Beat Estimates

by Zacks Equity Research

Editas (EDIT) reports narrower-than-expected loss in the first quarter of 2022 while its revenues beat estimates. Focus on lead candidate, EDIT-101.

Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Editas (EDIT) delivered earnings and revenue surprises of 8.64% and 44.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Editas Medicine (EDIT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Editas (EDIT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Editas (EDIT) Begins Dosing Pediatric Patients in Gene Drug Study

by Zacks Equity Research

Editas (EDIT) doses the first patient pediatric patient in the BRILLIANCE study on EDIT-101 for treating Leber congenital amaurosis 10 (LCA10).

Editas (EDIT) Soars 6.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Editas (EDIT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Editas' (EDIT) Q4 Loss Narrows, Revenues Trump Estimates

by Zacks Equity Research

Editas (EDIT) reports narrower-than-expected loss in the fourth quarter of 2021 while its revenues beat estimates. Focus remains on the development of lead candidate, EDIT-101.

Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Editas (EDIT) delivered earnings and revenue surprises of 21.79% and 181.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Drug/Biotech Stocks' Q4 Earnings on Feb 24: MRNA, EBS & More

by Zacks Equity Research

Let us take a look at five biotech/drug companies, namely, MRNA, EDIT, VIR, EBS and AERI, which are due to release their quarterly results on Feb 24.

Prothena (PRTA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Prothena (PRTA) delivered earnings and revenue surprises of 4.05% and 324.64%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Editas Medicine (EDIT) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Orphazyme (ORPH) Up on Plans of NDA Resubmission for Rare Drug

by Zacks Equity Research

Orphazyme (ORPH) is looking to resubmit its NDA for arimoclomol to the FDA for the treatment of Niemann-Pick disease type C in the United States. Shares rise.

Ultragenyx's (RARE) Q4 Earnings & Revenues Miss Estimates

by Zacks Equity Research

Ultragenyx (RARE) reports wider-than-expected loss in the fourth quarter of 2021 while revenues miss estimates.

Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q3

by Zacks Equity Research

Immunovant's (IMVT) earnings miss estimates in fiscal third-quarter, which ended on Dec 31, 2021. Focus remains on lead pipeline candidate batoclimab.

Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug

by Zacks Equity Research

Editas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe.

Seagen (SGEN) Gets Positive CHMP Opinion for Bladder Cancer Drug

by Zacks Equity Research

The CHMP gives a positive opinion on, and recommends approval to Seagen's (SGEN) Padcev as a monotherapy for treating adult patients with locally advanced/metastatic urothelial cancer.

Global Blood (GBT) Gets FDA Nod for Oxbryta Label Expansion

by Zacks Equity Research

The FDA approves Global Blood's (GBT) sNDA for Oxbryta to treat SCD in children aged four to less the 12 years, and NDA for a pediatric weight-based formulation of the drug.

uniQure (QURE) Falls on Data From Huntington's Disease Study

by Zacks Equity Research

uniQure (QURE) reports initial data on the first four patients enrolled in the lower-dose cohort of its ongoing phase I/II clinical trial of AMT-130 for treating Huntington's disease.

Bristol Myers' (BMY) Orencia Gets FDA Nod for New Indication

by Zacks Equity Research

The FDA approves Bristol Myers' (BMY) Orencia in combination with a calcineurin inhibitor and methotrexate to prevent acute graft versus host disease. This is the fourth FDA-approved indication for the drug.

Apellis (APLS), Sobi Get EU Nod for Rare Blood Disorder Drug

by Zacks Equity Research

The European Commission approves Apellis (APLS) and Sobi's Aspaveli for the treatment of paroxysmal nocturnal hemoglobinuria in adult patients. Shares rise.

Alnylam (ALNY) Files for Oxlumo Label Expansion in US & EU

by Zacks Equity Research

Alnylam (ALNY) files regulatory applications to the FDA and the EMA, seeking approval for a new indication of Oxlumo for the treatment of advanced primary hyperoxaluria type 1.